Oxymorphone Hydrochloride Tablet
Product Images NDC 72865-130

6 FDA label images from Xlcare Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Oxymorphone Hydrochloride (NDC 72865-130). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xlcare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

10 mg- 100 Count (Oxymorphone 10 mg)

10 mg- 100 Count (Oxymorphone 10 mg)
Label for Oxymorphone Hydrochloride Tablets USP 10 mg from XLCare Pharmaceuticals, Inc. The label shows the product name, strength (10 mg), dosage form (tablets), and package quantity (100 tablets). It includes storage and dispensing instructions and manufacturer information for XLCare Pharmaceuticals, Inc., and Ascent Pharmaceuticals, Inc. The label also has a barcode and notes that the product is Rx only.*
FDA Label Image

5 mg- 100 Count (Oxymorphone 5 mg)

5 mg- 100 Count (Oxymorphone 5 mg)
Label for Oxymorphone Hydrochloride Tablets USP 5 mg by XLCare Pharmaceuticals, Inc. The label includes the NDC number 72865-130-01 and specifies the bottle contains 100 tablets for Rx only. Storage and dispensing instructions, manufacturer and labeler information are also present.*
FDA Label Image

Structure (Struct)

Structure (Struct)
Chemical structure of oxycodone hydrochloride, the active ingredient in OXYMORPHONE HYDROCHLORIDE tablets by XLCare Pharmaceuticals, Inc.*
FDA Label Image

Table 1 (Table 1)

Table 1 (Table 1)
A data table titled 'Adverse Reactions Reported in Placebo-Controlled Trials' comparing the incidence of various adverse reactions between Oxymorphone Hydrochloride Tablets (N=557) and Placebo (N=270). The table lists reactions such as nausea, pyrexia, somnolence, vomiting, pruritus, headache, dizziness excluding vertigo, constipation, and confusion, with corresponding percentage values for each group.*
FDA Label Image

Table 2 (Table 2)

Table 2 (Table 2)
Text panel detailing drug interaction warnings for oxymorphone hydrochloride tablets. It covers the clinical impact, intervention measures, and examples related to concomitant use with alcohol, benzodiazepines and other CNS depressants, serotonergic drugs, monoamine oxidase inhibitors (MAOIs), mixed agonist/antagonist opioid analgesics, muscle relaxants, diuretics, anticholinergic drugs, and cimetidine.*
FDA Label Image

Table 3 (Table 3)

Table 3 (Table 3)
A data table displaying mean (±SD) pharmacokinetic parameters for Oxymorphone Hydrochloride tablets at various dosages (5 mg, 10 mg, 20 mg) under single dose and multiple dose regimens. Parameters include Cmax (ng/mL), AUC (ng·hr/mL), and T1/2 (hr), with notes defining NA and dosing frequency for multiple doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.